Skip to main content
Fig. 7 | BMC Neurology

Fig. 7

From: Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial

Fig. 7

IL-22–expressing CD4+ T cells and GM volume changes in RRMS. Higher percentage of IL-22–expressing CD4+ T cells at baseline correlated with smaller decreases in GM volume from baseline to 6 months in treated patients with RRMS. GM gray matter; IL interleukin; RRMS relapsing–remitting multiple sclerosis

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us